A more likely explanation stems from the study by Tsai et al., who demonstrated that PLX4720 does inhibits wildtype BRAF kinase activity in several tumor cell lines, but only at higher concentrations than those effective on cells harboring a mutated BRAFV600E kinase27. The gene discussed is BRAF; the disease is neoplasm.